anti-B7-H4 monoclonal antibody NC762

{
  "id": "MLC-T-ONC-010145",
  "term": "anti-B7-H4 monoclonal antibody NC762",
  "field": "Oncology and biomedicine",
  "definition": "A humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-B7-H4 monoclonal antibody NC762 binds to B7-H4 on the surface of tumor cells. This may induce antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells, which leads to the inhibition of tumor cell proliferation. In addition, the Fc region of NC762 contains three point mutations. This enhances its binding affinity for human FcgammaRIIIa receptors (CD16a) on natural killer (NK) cells, resulting in enhanced ADCC against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses. However, the anti-tumor activity of NC762 is not dependent upon T cells.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-b7-h4-monoclonal-antibody-nc762/"
}